Mario Tanguay, Université de Montréal

Research

Read how they describe their research on their Université de Montréal profile.

Développement clinique du médicament Développement du médicament Pharmacologie clinique

Latest papers

Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females.
Clinical pharmacology in drug development · 2023 · first author
A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2019
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Clinical pharmacokinetics · 2015 · senior author

All 6 publications

6 publications.

01

Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females.

Tanguay M, Cometti B, Boudreault S

Clinical pharmacology in drug development2023First author

DOI: 10.1002/cpdd.1300 PMID: 37439025

02

A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers

Irfan Qureshi, Meghan Lovegren, Victoria Wirtz, Richard Larouche, Mario Tanguay, Matt S. Anderson, Sonja Hartmann, Vlad Coric, Robert Berman

Clinical Pharmacology in Drug Development20199 citations

DOI: 10.1002/cpdd.747 PMID: 31610101

03

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M

Clinical pharmacokinetics20154 citationsSenior author

DOI: 10.1007/s40262-014-0202-x PMID: 25358450

04

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M

Journal of pharmacokinetics and pharmacodynamics20151 citationsSenior author

DOI: 10.1007/s10928-015-9416-2 PMID: 25895899

05

Pharmacokinetic characterization of baclofen in patients with chronic kidney disease: dose adjustment recommendations

Raphaël Vlavonou, Marc M. Perreault, Olivier Barrière, Éric Shink, Pierre‐Olivier Tremblay, Richard Larouche, Vincent Pichette, Mario Tanguay

The Journal of Clinical Pharmacology201455 citationsSenior author

DOI: 10.1002/jcph.247 PMID: 24414993

06

Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.

Trabelsi F, Bartůnek A, Vlavonou R, Navrátilová L, Dubé C, Tanguay M, Hauser T

International journal of clinical pharmacology and therapeutics2012

DOI: 10.5414/cp201687 PMID: 22762855

Frequent collaborators

Other

Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Fahima Nekka

Faculty

2 shared papers, latest 2015

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student: Développement clinique du médicament Dear Professor Tanguay, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Comparative Bioavailability of Two Daily Subcutaneous Doses Versus a Single Dose of Intramuscular and Vaginal Progesterone Formulations in Healthy Postmenopausal Females." (2023), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]